ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Clinical trials for ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) explained in plain language.
Never miss a new study
Get alerted when new ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC) trials appear
Sign up with your email to follow new studies for ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Common nerve drug tested for rosacea redness
Symptom relief CompletedThis study tested if gabapentin, a medication often used for nerve pain, could reduce the persistent redness and sudden flushing associated with rosacea. It involved 50 participants with this specific skin condition and compared gabapentin's effects to a standard rosacea treatmen…
Matched conditions: ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Phase: PHASE1 • Sponsor: First Affiliated Hospital of Chongqing Medical University • Aim: Symptom relief
Last updated Mar 27, 2026 12:40 UTC
-
Face-Splitting test shows gel may calm rosacea redness
Symptom relief CompletedThis study tested whether a prescription gel called 0.33% brimonidine can reduce persistent facial redness in people with rosacea. Researchers applied the gel to one side of participants' faces and a placebo gel to the other side to compare immediate effects, then had participant…
Matched conditions: ROSACEA SUBTYPE 1 (ERYTHEMATOTELANGIECTATIC)
Phase: PHASE4 • Sponsor: Istanbul Training and Research Hospital • Aim: Symptom relief
Last updated Mar 13, 2026 15:05 UTC